rifampin vs vorapaxar
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of rifampin and vorapaxar. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
moderate Known Drug Interaction
Strong CYP3A Inducers Avoid concomitant use of ZONTIVITY with strong inducers of CYP3A (e.g., rifampin, carbamazepine, St.
Rifampin is an antibiotic medicine. It fights bacteria in your body to treat infections.
Vorapaxar (Zontivity) helps prevent blood clots if you have had a heart attack or have peripheral artery disease. It works by stopping platelets in your blood from sticking together and forming clots.
Rifampin treats tuberculosis (TB) and helps eliminate the bacteria that cause meningitis from your nose and throat. It is important to use rifampin only for infections that are proven or strongly suspected to be caused by bacteria. This helps to prevent bacteria from becoming resistant to the medicine.
Vorapaxar is used to lower the chance of having serious heart problems if you have a history of heart attack or peripheral artery disease (PAD). PAD is when you have narrowed arteries that reduce blood flow to your limbs. This medicine can help prevent heart death, heart attack, stroke, and the need for urgent procedures to open blocked heart arteries.
Rifampin works by stopping bacteria from growing and multiplying. It does this by blocking a key enzyme that the bacteria need to make proteins. This helps your body fight off the infection.
Vorapaxar is a PAR-1 antagonist, which means it blocks a specific receptor on platelets. This receptor, called protease-activated receptor-1 (PAR-1), normally causes platelets to clump together. By blocking PAR-1, vorapaxar helps prevent blood clots from forming.
- • Heartburn
- • Upset stomach
- • Loss of appetite
- • Nausea
- • Vomiting
- • Bleeding
- Drug Interaction 970
- Drug Reaction With Eosinophilia And Systemic Symptoms 727
- Nausea 628
- Condition Aggravated 550
- Pyrexia 541
No adverse event reports.
Rifampin can cause liver problems. Tell your doctor right away if you have yellowing of the skin or eyes, dark urine, or stomach pain. Rifampin can also cause blood problems. Tell your doctor if you have unusual bleeding or bruising.
Vorapaxar can cause serious bleeding, including bleeding in the brain, which can be fatal. You should not take this medicine if you have a history of stroke, transient ischemic attack (TIA), or bleeding in the brain. Also, do not take it if you have active bleeding.
Tell your doctor if you are pregnant or plan to become pregnant. Rifampin can make birth control pills less effective, so use other forms of birth control. Talk to your doctor if you are breastfeeding.
It is not known if vorapaxar will harm an unborn baby. Talk to your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.
How to Read This rifampin vs vorapaxar Comparison
rifampin is classified in the Rifamycin Antibiotic drug class, while vorapaxar sits within the PAR-1 Antagonist (Antiplatelet) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, rifampin has 3,416 submissions while vorapaxar has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to rifampin causes your body to break down vorapaxar too quickly, which may prevent the medicine from working as it should.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for rifampin or vorapaxar.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.